TBX-3400

N/A

Report date: 2024/11/23 20:00:08

Base Information

Drug NameTBX-3400
Drug Alias Nameautologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC) (Taiga Biotechnologies)TBX-3400
ClassificationCell and gene therapy > Cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunologic cytotoxicityCell replacements
TargetsUpdating
Therapy Area/IndicationsSolid tumoursMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTaiga Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesTaiga Biotechnologies Inc
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A